437 related articles for article (PubMed ID: 25483215)
21. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
[TBL] [Abstract][Full Text] [Related]
22. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
[TBL] [Abstract][Full Text] [Related]
23. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
Barco S; Lankeit M; Binder H; Schellong S; Christ M; Beyer-Westendorf J; Duerschmied D; Bauersachs R; Empen K; Held M; Schwaiblmair M; Fonseca C; Jiménez D; Becattini C; Quitzau K; Konstantinides S
Thromb Haemost; 2016 Jul; 116(1):191-7. PubMed ID: 27010343
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
25. Rivaroxaban for the treatment of pulmonary embolism.
Vanassche T; Verhamme P
Adv Ther; 2013 Jun; 30(6):589-606. PubMed ID: 23807375
[TBL] [Abstract][Full Text] [Related]
26. Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.
Imberti D; Becattini C; Bernardi E; Camporese G; Cuccia C; Dentali F; Paretti D
Intern Emerg Med; 2018 Oct; 13(7):1037-1049. PubMed ID: 29520700
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
29. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study.
Prandoni P
Eur J Haematol; 2012 Oct; 89(4):281-7. PubMed ID: 22834998
[TBL] [Abstract][Full Text] [Related]
32. Possible Rivaroxaban Failure during the Postpartum Period.
Rudd KM; Winans AR; Panneerselvam N
Pharmacotherapy; 2015 Nov; 35(11):e164-8. PubMed ID: 26598101
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
34. Rivaroxaban in acute coronary syndromes--is it prime time?
Asrar ul Haq M; van Gaal WJ
Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
[TBL] [Abstract][Full Text] [Related]
35. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
[TBL] [Abstract][Full Text] [Related]
36. Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
Baruch L; Sherman O
Ann Pharmacother; 2013 Sep; 47(9):1210-2. PubMed ID: 24259738
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.
Wang Y; Wang C; Chen Z; Zhang J; Liu Z; Jin B; Ying K; Liu C; Shao Y; Jing Z; Meng IL; Prins MH; Pap AF; Müller K; Lensing AW;
Thromb J; 2013 Dec; 11(1):25. PubMed ID: 24341332
[TBL] [Abstract][Full Text] [Related]
38. Who could benefit most from treatment of acute pulmonary embolism with rivaroxaban? Commentary to the article: "Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy….
Undas A
Kardiol Pol; 2016; 74(7):701-2. PubMed ID: 27401298
[No Abstract] [Full Text] [Related]
39. Use of rivaroxaban could trim hospital spending in treating pulmonary embolism.
Caffrey MK
Am J Manag Care; 2014 May; 20(8 Spec No.):E12. PubMed ID: 25617931
[No Abstract] [Full Text] [Related]
40. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
